Drug Patents owned by Purdue Pharma Lp

1. List of Adhansia Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568841 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10500162 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10449159 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512613 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292939 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10111839 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10512612 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10292938 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US9974752 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10688060 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10507186 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Oct, 2035

(12 years from now)

US10722473 PURDUE PHARMA LP Methods and compositions particularly for treatment of attention deficit disorder
Nov, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 27, 2022
M Jun 28, 2024

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 February, 2019

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

2. List of Hysingla Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8529948 PURDUE PHARMA LP Pharmaceutical formulation containing gelling agent
Aug, 2022

(5 months ago)

US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9750703 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9872837 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9861584 PURDUE PHARMA LP Tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US8808740 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

US9572779 PURDUE PHARMA LP Encased tamper resistant controlled release dosage forms
Dec, 2031

(8 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 20 November, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HYSINGLA ER before it's patent expiration?
More Information on Dosage

3. List of Oxycontin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(2 years from now)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms
Nov, 2023

(9 months from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US8894988 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US8894987 PURDUE PHARMA LP Tamper resistant dosage forms
Mar, 2030

(7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2010

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

4. List of Targiniq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168252 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9345701 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9056051 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9084729 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9511066 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9161937 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9283221 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US8969369 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9283216 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(8 months ago)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(2 months from now)

US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(2 months from now)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(2 months from now)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(2 months from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in